Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27914491 | 0.89 | TSHR (0.40) | HPGDSMN1; SMN2MAPK1CYP3A4MEN1 | |
| SCHEMBL28178897 | 0.83 | CYP2A6 (0.40) | MAPTMAPK1HTTCYP3A4 | |
| SCHEMBL28165369 | 0.83 | CHKA (0.39) | MAPTNPSR1LMNA | |
| SCHEMBL28757072 | 0.81 | — | — | |
| SCHEMBL28261507 | 0.80 | MAPK1 (0.33) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL27760686 | 0.80 | ENPP2 (0.36) | MAPTNPSR1HPGDNPC1RAB9A | |
| SCHEMBL2115712 | 0.80 | — | — | |
| SCHEMBL11257044 | 0.80 | MAPT (0.41) | MAPTNPSR1HPGDNPC1RAB9A | |
| SCHEMBL2115142 | 0.78 | — | — | |
| SCHEMBL27457816 | 0.78 | MEN1 (0.41) | NPC1RAB9ASMN1; SMN2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116888118-A | Phenyl dihydropyrimidine compound and application thereof | 和博医药有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-103370321-A | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the PI3K/AKT pathway | BAYER IP GMBH | 2013-10-23 | — | — | CN | claimed |
| EP-1635815-A4 | METHODS AND COMPOUNDS FOR THE TREATMENT OF VASCULAR STENOSIS | BETH ISRAEL HOSPITAL (US) | 2009-03-25 | — | — | EP | claimed |
| US-20060240014-A1 | Methods and compounds for the treatment of vascular stenosis | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2006-10-26 | — | — | US | claimed |
| EP-1635815-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF VASCULAR STENOSIS | Beth Israel Deaconess Medical Center (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050261283-A1 | Methods and compositions for the treatment of graft failure | BETH ISRAEL DEACONESS MEDICAL CENTER | 2005-11-24 | — | — | US | claimed |
| EP-1509219-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GRAFT FAILURE | Beth Israel Deaconess Medical Center (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2004108130-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF VASCULAR STENOSIS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2004-12-16 | — | — | WO | claimed |
| WO-2003094904-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GRAFT FAILURE | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2003-11-20 | — | — | WO | claimed |
| US-5728708-A | ANTITUMOR AGENTS | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | claimed |
| JP-6184116-A | — | — | None | — | — | JP | disclosed |
| EP-4289842-A4 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | Hepagene Therapeutics (HK) Limited (HK) | 2025-01-08 | — | — | EP | disclosed |
| CN-115246822-B | Pyrimidine compound, and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-10-29 | — | — | CN | disclosed |
| US-20240246978-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-118159055-A | Organic light-emitting layer, organic electroluminescent device, and electronic device | 华为终端有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-5516775-A | TO INHIBIT PROTEIN KINASE C | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| US-5516775-A | TO INHIBIT PROTEIN KINASE C | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| JP-H06184116-A | PHARMACEUTICAL COMPOSITION | CIBA GEIGY AG | 1994-07-05 | — | — | JP | disclosed |
| CN-1016668-B | METHOD FOR PREPARATION OF MEDICINES COMPOSITION FOR TREATING ARTERIOSCLEROSIS | KANTO ISHI PHARMA CO LTD (JP) | 1992-05-20 | — | — | CN | disclosed |
| CN-87105862-A | The treatment atherosclerosis drug that contains pyrimido [2,1-b] benzothiazole derivant | — | 1988-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261283-A1 | Methods and compositions for the treatment of graft failure | PDGFRB, PDGFRA, PDGFA | MAPT 4727/4885NPSR1 2472/4885HPGD 998/4885 |
| US-20240246978-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | TYMP, DPYD, PAH | MAPT 12/4885NPSR1 4631/4885HPGD 490/4885 |
| US-20060240014-A1 | Methods and compounds for the treatment of vascular stenosis | MTOR, PIK3CA, PIK3C2B | MAPT 4749/4885NPSR1 2820/4885HPGD 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.